CAR-T Digest- August 2020

CAR-T Digest- August 2020

Tessa Therapeutics published data from two Phase 1/2 trials of CD30 CAR-T therapy in R/R Hodgkin lymphoma

06 Aug 2020

TT11 (Autologous CD30 CAR-T cell therapy) – Tessa Therapeutics

  • Combined results from two Phase 1/2 trials in the Journal of Clinical Oncology led by Baylor college of medicine and the University of North Carolina Lineberger comprehensive cancer center
  • Based on these results Tessa has registered a pivotal Phase 2 trial (R/R CD30+ classical Hodgkin Lymphoma), expected to initiate in Q4’20
  • Patients received TT11 CAR-T after fludarabine-based lymphodepletion

Trial details and results:

  • A Phase 1b/2 to establish a safe dose of T Lymphocytes expressing the CD30.CAR for R/R CD30+ Hodgkin’s Lymphoma and CD30+ Non-Hodgkin’s Lymphoma (N=40)
  • A Phase 1 study of relapsed CD30 expressing lymphoma treated with CD30.CAR-T cells to learn more about the way the CD30.CAR-T cells are working and how long they last in the body (N=66)
  • Efficacy:
    • ORR: 72% (in 32 patients), Complete response: 59% (19 patients)
    • 1-year PFS: 36% (95% CI, 21% to 51%); OS: 94% (95% CI, 79% to 99%)
  • Safety:
    • Cytokine release syndrome: 10 patients (grade 1)
    • Most common toxicities: Grade 3 or higher hematologic adverse events

Tessa Therapeutics shows positive Phase 1/2 data for autologous CD30 CAR-T cell therapy in R/R, HL

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share

CI Scientists Remarks: 

  • CD30 is a validated target of classical Hodgkin lymphoma and some non-Hodgkin lymphomas. The CD30-targeting CAR enables the recognition and elimination of CD30+ lymphoma cells
  • Tessa is collaborating with Baylor college of medicine to develop CAR-Ts since 2016
  • Tessa Therapeutics has access to patents and data from both the trials
  • Based on these results, the US FDA has granted CD30 CAR-T Cell Therapy Regenerative Medicine Advanced Therapy (RMAT) Designation for the treatment of R/R CD30+ classical Hodgkin Lymphoma
  • Tessa Therapeutics is exploring the potential of CD30.CAR-T therapy in CD30+ expressing non-Hodgkin lymphomas and CD30+ lymphomas and HER2 targeting CAR-T (HER2+ solid tumors)

– Jesanto Mathew, CI Scientists

For full story click here

Home